Abstract
Background As the COVID-19 pandemic evolves, there is a need for reliable and scalable seroepidemiology methods to estimate incidence, monitor the dynamics of population-level immunity, and guide mitigation and immunization policies. Our aim was to evaluate the reliability of normalized ELISA optical density (nOD) at a single dilution as a predictor of SARS-CoV-2 immunoglobulin titers derived from serial dilutions.
Methods We conducted serial serological surveys of a community-based cohort from the city of Salvador, Brazil after two sequential COVID-19 epidemic waves. Anti-SARS-CoV-2 spike protein immunoglobulin G (anti-S IgG) ELISA (Euroimmun AG) was performed with serial 3-fold dilutions of sera from 54 of the 1101 cohort participants. We estimated interpolated ELISA titers, used parametric models to fit the relationship between nOD at a single 1:100 dilution and interpolated titers, and assessed the correlation between changes in nOD and changes in titers.
Results The relationship between nOD at a single 1:100 dilution and interpolated titers fit a log-log curve, with a residual standard error of 0.304. We derived a conversion table of nOD to interpolated titer values. Additionally, there was a high correlation between changes in nOD and changes in interpolated titers between paired serial samples (r = 0.836, ρ = 0.873). Changes in nOD reliably predicted increases and decreases in titers, with 98.1% agreement (κ = 95.9%).
Conclusion Single nOD measurements can reliably estimate SARS-CoV-2 antibody titers, significantly reducing time, labor, and resource needs when conducting large-scale serological surveys to ascertain population-level changes in exposure and immunity.
Highlights
Optical density at a single dilution reliably estimates SARS-CoV-2 antibody titers
Serial optical density measurements accurately identify changes in serostatus
Using single optical density values can significantly reduce resource use in serosurveys
Competing Interest Statement
A.I.K serves as an expert panel member for Reckitt Global Hygiene Institute, scientific advisory board member for Revelar Biotherapeutics and a consultant for Tata Medical and Diagnostics and Regeneron Pharmaceuticals, and has received grants from Merck, Regeneron Pharmaceuticals and Tata Medical and Diagnostics for research related to COVID-19, all of which are outside the scope of the submitted work. Other authors declare no conflict of interest.
Funding Statement
This work was supported by grants from the National Institutes of Health (R01 AI052473, U01AI088752, R01 TW009504 and R25 TW009338 to A.I.K.), UK Medical Research Council (MR/T029781/1 to F.C.), Wellcome Trust (102330/Z/13/Z; 218987/Z/19/Z to F.C.), Brazilian National Council for Scientific and Technological Development (research scholarship to G.S.R.), Bahia Foundation for Research Support (SUS0019/2021 to G.S.R.), and the Sendas Family Fund at the Yale School of Public Health (A.I.K.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Brazilian National Commission for Ethics in Research and the Yale University Human Research Protection Program gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding statement This work was supported by grants from the National Institutes of Health (R01 AI052473, U01AI088752, R01 TW009504 and R25 TW009338 to A.I.K.), UK Medical Research Council (MR/T029781/1 to F.C.), Wellcome Trust (102330/Z/13/Z; 218987/Z/19/Z to F.C.), Brazilian National Council for Scientific and Technological Development (research scholarship to G.S.R.), Bahia Foundation for Research Support (SUS0019/2021 to G.S.R.), and the Sendas Family Fund at the Yale School of Public Health (A.I.K.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Ethics statement The study was approved by the Institutional Review Boards of the Gonçalo Moniz Institute, Oswaldo Cruz Foundation (Fiocruz) and the Brazilian National Commission for Ethics in Research (CAAE 35405320.0.1001.5030 and 17963519.0.0000.0040), and the Yale University Human Research Protection Program (2000031554).
Conflicts of Interest A.I.K serves as an expert panel member for Reckitt Global Hygiene Institute, scientific advisory board member for Revelar Biotherapeutics and a consultant for Tata Medical and Diagnostics and Regeneron Pharmaceuticals, and has received grants from Merck, Regeneron Pharmaceuticals and Tata Medical and Diagnostics for research related to COVID-19, all of which are outside the scope of the submitted work. Other authors declare no conflict of interest.
Data Availability
All data produced in the present study are available upon reasonable request to the authors